Results

1–5 of 5 results for Philip J. Ferrone

Pooled Safety Analysis of Aflibercept 8 mg in the CANDELA PHOTON and PULSAR Trials
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2023
Pediatric Cases That All Retina Surgeons Will Encounter
Audina M. Berrocal, MD FASRS
Yoshihiro Yonekawa, MD, FASRS
Philip J. Ferrone, MD, FASRS
Caroline Baumal, MD, FASRS
Lejla Vajzovic, MD, FASRS
Emmanuel Chang, MD PhD FACS FASRS
Webinars and Journal Clubs
2022
Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019
Complications or Are They: Why We Can NEVER Get Enough ReST
Jeffrey S. Heier, MD
Peter K. Kaiser, MD FASRS
Geoffrey G. Emerson, MD, PhD, FASRS
J. Michael Jumper, MD, FASRS
Ehab N. ELRAYES, MD, PhD ,FASRS
Daniel Simhaee, MD
ASSAF DOTAN, MD
Paul Hahn, MD, PhD, FASRS
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2018
Aflibercept-Related Sterile Intraocular Inflammation
Philip J. Ferrone, MD, FASRS
Updates from the Field
2018